Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program - Seite 2

Jan Hoflack, Co-founder and Chief Medical Officer of Oncodesign Precision Medicine, added: “We have been developing Nanocyclix technology since 2010: these are small kinases inhibitors macrocyclic molecules. Their 3-dimensional shape enables them to interact with their target with great efficacy and specificity. Since 2010, development programs based on Nanocyclix have been designed, in partnership and internally, leading to 3 molecules in clinical phase today. The multitude of data obtained on more than 12,000 molecules represents a treasure of information that we are going to exploit using AI methods (Machine Learning and Deep Learning) to accelerate our Drug Discovery process. The 3D aspect, which is essential for Nanocyclix, is currently poorly explored by AI methods. Furthermore, the small macrocyclic molecules developed with Nanocyclix are difficult to generate efficiently using current methods. The use of AI on our proprietary database in this context has the potential to accelerate significantly the discovery of clinical candidates while reducing the costs associated with this process.”

About Oncodesign Precision Medicine (OPM)

Oncodesign Precision Medicine (OPM), the result of the transfer of Oncodesign's Biotech and AI activities, is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers.

OPM's innovative technologies are (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and (iii) Promethe for the design and selection of radiolabeled biological molecules for systemic radiotherapy.

From these technologies, OPM has built a portfolio of therapeutic products. A first drug candidate based on the Nanocyclix technology entered the clinical phase in 2022, in partnership with SERVIER (which exercised its option for an exclusive worldwide license on the program) to treat Parkinson's disease. OPM-101 is OPM's second candidate to enter the clinic, in the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier to discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology. In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase I. Finally, OPM has a significant portfolio of early-stage projects with Nanocyclix and Promethe in oncology. With this portfolio of molecules and diversified therapeutic targets, OPM's mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital cluster, OPM has 25 employees.